Adagene (ADAG) Competitors $1.98 0.00 (0.00%) As of 10:43 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADAG vs. SLDB, CMPX, ADCT, AQST, SNDL, CYRX, IVA, ARCT, ACB, and ATXSShould you be buying Adagene stock or one of its competitors? The main competitors of Adagene include Solid Biosciences (SLDB), Compass Therapeutics (CMPX), ADC Therapeutics (ADCT), Aquestive Therapeutics (AQST), SNDL (SNDL), Cryoport (CYRX), Inventiva (IVA), Arcturus Therapeutics (ARCT), Aurora Cannabis (ACB), and Astria Therapeutics (ATXS). These companies are all part of the "pharmaceutical products" industry. Adagene vs. Its Competitors Solid Biosciences Compass Therapeutics ADC Therapeutics Aquestive Therapeutics SNDL Cryoport Inventiva Arcturus Therapeutics Aurora Cannabis Astria Therapeutics Adagene (NASDAQ:ADAG) and Solid Biosciences (NASDAQ:SLDB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk, profitability and community ranking. Does the media refer more to ADAG or SLDB? In the previous week, Solid Biosciences had 9 more articles in the media than Adagene. MarketBeat recorded 10 mentions for Solid Biosciences and 1 mentions for Adagene. Adagene's average media sentiment score of 1.87 beat Solid Biosciences' score of 0.96 indicating that Adagene is being referred to more favorably in the media. Company Overall Sentiment Adagene Very Positive Solid Biosciences Positive Does the MarketBeat Community favor ADAG or SLDB? Solid Biosciences received 259 more outperform votes than Adagene when rated by MarketBeat users. However, 79.31% of users gave Adagene an outperform vote while only 69.46% of users gave Solid Biosciences an outperform vote. CompanyUnderperformOutperformAdageneOutperform Votes2379.31% Underperform Votes620.69% Solid BiosciencesOutperform Votes28269.46% Underperform Votes12430.54% Do institutionals and insiders believe in ADAG or SLDB? 9.5% of Adagene shares are owned by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are owned by institutional investors. 21.2% of Adagene shares are owned by company insiders. Comparatively, 1.9% of Solid Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has better earnings and valuation, ADAG or SLDB? Adagene has higher earnings, but lower revenue than Solid Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdagene$103.20K903.82-$18.95MN/AN/ASolid Biosciences$8.09M43.21-$96.01M-$2.99-1.51 Which has more volatility and risk, ADAG or SLDB? Adagene has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500. Comparatively, Solid Biosciences has a beta of 2.22, indicating that its stock price is 122% more volatile than the S&P 500. Do analysts recommend ADAG or SLDB? Adagene currently has a consensus price target of $8.00, indicating a potential upside of 304.04%. Solid Biosciences has a consensus price target of $14.90, indicating a potential upside of 230.38%. Given Adagene's higher probable upside, equities analysts clearly believe Adagene is more favorable than Solid Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adagene 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Solid Biosciences 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 3 Strong Buy rating(s) 3.23 Is ADAG or SLDB more profitable? Adagene's return on equity of 0.00% beat Solid Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets AdageneN/A N/A N/A Solid Biosciences N/A -58.75%-47.84% SummaryAdagene and Solid Biosciences tied by winning 8 of the 16 factors compared between the two stocks. Get Adagene News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADAG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADAG vs. The Competition Export to ExcelMetricAdagenePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$93.28M$6.93B$5.60B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E RatioN/A8.8527.2320.02Price / Sales903.82256.44417.65154.33Price / CashN/A65.8538.2534.64Price / Book1.236.617.124.70Net Income-$18.95M$143.93M$3.23B$247.97M7 Day Performance12.50%3.84%2.74%2.64%1 Month Performance16.54%11.14%8.94%6.39%1 Year Performance-31.96%4.35%31.59%13.95% Adagene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADAGAdagene2.7362 of 5 stars$1.98flat$8.00+304.0%-32.0%$93.28M$103.20K0.00260Gap DownSLDBSolid Biosciences3.7726 of 5 stars$4.62+1.8%$14.90+222.5%-38.6%$358.12M$8.09M-1.52100Analyst RevisionCMPXCompass Therapeutics3.722 of 5 stars$2.57+2.8%$13.13+410.7%+99.2%$355.39M$850K-6.9520Positive NewsADCTADC Therapeutics2.8524 of 5 stars$3.57-2.7%$7.75+117.1%+13.2%$354.07M$75.82M-1.49310News CoveragePositive NewsAnalyst RevisionGap UpAQSTAquestive Therapeutics1.7624 of 5 stars$3.54-0.6%$10.14+186.5%+21.4%$351.62M$54.23M-7.87160Positive NewsAnalyst RevisionSNDLSNDL3.6087 of 5 stars$1.33+0.8%$3.63+172.6%-34.8%$349.49M$927.61M-4.29580News CoverageCYRXCryoport3.5329 of 5 stars$6.96-0.6%$11.00+58.0%-34.9%$348.95M$232.13M-2.061,020Insider TradeIVAInventiva2.1469 of 5 stars$3.63+0.4%$10.40+186.9%+8.3%$346.78M$9.20M0.00100News CoverageGap DownARCTArcturus Therapeutics3.2664 of 5 stars$12.54-2.0%$53.50+326.6%-61.6%$340.10M$131.27M-5.65180News CoveragePositive NewsAnalyst RevisionGap UpACBAurora Cannabis0.3933 of 5 stars$5.82+1.7%N/A+2.4%$327.17M$320.81M116.421,340Upcoming EarningsATXSAstria Therapeutics2.3901 of 5 stars$5.79-3.3%$30.00+418.1%-36.2%$326.75MN/A-2.7730News CoverageAnalyst Revision Related Companies and Tools Related Companies SLDB Competitors CMPX Competitors ADCT Competitors AQST Competitors SNDL Competitors CYRX Competitors IVA Competitors ARCT Competitors ACB Competitors ATXS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADAG) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adagene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adagene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ADAG Stock Free ADAG Stock Alerts